var data={"title":"Intra-amniotic infection (clinical chorioamnionitis or triple I)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Intra-amniotic infection (clinical chorioamnionitis or triple I)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/contributors\" class=\"contributor contributor_credentials\">Alan Thevenet N Tita, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/contributors\" class=\"contributor contributor_credentials\">Vincenzo Berghella, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/contributors\" class=\"contributor contributor_credentials\">Vanessa A Barss, MD, FACOG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 28, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Historically, infection of the chorion, amnion, or both was termed &quot;chorioamnionitis.&quot; Although this term remains in common use, the term &quot;intra-amniotic infection&quot; (IAI) is also commonly used since infection often involves the amniotic fluid, fetus, umbilical cord, or placenta as well as the fetal membranes. Adding to the complexity, the term &quot;histologic chorioamnionitis&quot; has been used to describe cases without the typical clinical or microbiological findings associated with acute infection. These cases may be the result of sterile inflammation or use of insensitive microbiologic techniques.</p><p>In 2015, a National Institute of Child Health and Human Development Workshop expert panel recommended use of the term &ldquo;triple I&rdquo; to address the heterogeneity of this disorder (<a href=\"image.htm?imageKey=OBGYN%2F107670\" class=\"graphic graphic_table graphicRef107670 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/1\" class=\"abstract_t\">1</a>]. The term triple I refers to intrauterine infection or inflammation or both and is defined by strict diagnostic criteria (see <a href=\"#H1457755771\" class=\"local\">'Diagnostic criteria'</a> below), but this terminology has not been universally adopted [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/2\" class=\"abstract_t\">2</a>]. </p><p class=\"headingAnchor\" id=\"H24363502\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Migration of cervicovaginal flora through the cervical canal is the most common pathway to IAI. Uncommonly, the pathway to IAI is hematogenous as a result of maternal bacteremia (eg, <em>Listeria</em> <em>monocytogenes</em>) infecting the intervillous space or from contamination of the amniotic cavity as a result of an invasive procedure (eg, fetoscopy). Infection from the peritoneum via the fallopian tubes has also been postulated but is likely rare [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/3\" class=\"abstract_t\">3</a>]. Subsequent activation of the maternal and fetal inflammatory response systems generally leads to labor <span class=\"nowrap\">and/or</span> rupture of membranes. (See <a href=\"topic.htm?path=pathogenesis-of-spontaneous-preterm-birth\" class=\"medical medical_review\">&quot;Pathogenesis of spontaneous preterm birth&quot;</a>.)</p><p>Local host factors likely play a role in facilitating or preventing infection. The cervical mucus plug, membranes, and placenta provide barriers to ascending and transplacental infection, while rupture of membranes removes barriers. There is some evidence that the fetal membranes have antimicrobial activity [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Cells within fetal membranes appear to mediate innate immune responses through activation of toll-like receptors, key modulators of the innate immune response that recognize components of bacteria and viruses [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Lactobacilli in the vagina may induce changes in the flora that impair the virulence of pathogenic organisms.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">INCIDENCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported incidence of IAI in the United States varies widely among publications [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/8\" class=\"abstract_t\">8</a>]. The variation is due to several factors, including differences in ascertainment (prospective studies report higher rates than retrospective studies), differences in prevalence of risk factors in the populations studied, use of different diagnostic criteria (eg, clinical versus histologic), and temporal changes in obstetric practice [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/9-11\" class=\"abstract_t\">9-11</a>].</p><p>The frequency of IAI ranges from 40 to 70 percent among pregnancies delivered preterm because of preterm labor or preterm premature rupture of membranes (PPROM) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/12\" class=\"abstract_t\">12</a>]. In a systematic review, 20 to 25 percent of pregnancies with PPROM not treated with antibiotics developed IAI [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/13\" class=\"abstract_t\">13</a>].</p><p>At term, IAI complicates approximately 1 to 4 percent of deliveries overall [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/14-16\" class=\"abstract_t\">14-16</a>]. However, at term it has been diagnosed in 7 percent of women with rupture of membranes before onset of labor (PROM) (40 percent of those with PROM &gt;24 hours), 12 percent of women in labor who undergo a primary cesarean delivery after labor, and 20 percent of women who have more than eight digital vaginal examinations [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17,18\" class=\"abstract_t\">17,18</a>]. </p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Longer length of labor and length of ruptured membranes may be the most important risk factors for IAI. Several other obstetric factors have been associated with an increased risk for IAI, including multiple digital vaginal examinations (especially with ruptured membranes), cervical insufficiency, nulliparity, meconium-stained amniotic fluid, internal fetal or uterine monitoring, presence of genital tract pathogens (eg, sexually transmitted infections, group B <em>Streptococcus</em>, bacterial vaginosis), alcohol and tobacco use, and previous IAI [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/10,18-24\" class=\"abstract_t\">10,18-24</a>]. An increasing number of digital examinations may be a consequence of longer labor rather than an independent risk factor, particularly prior to membrane rupture [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/25\" class=\"abstract_t\">25</a>].</p><p>There is no strong evidence of an increased risk of IAI in pregnancies exposed to mechanical methods of cervical ripening versus prostaglandins; however, trials typically excluded women with ruptured membranes. (See <a href=\"topic.htm?path=techniques-for-ripening-the-unfavorable-cervix-prior-to-induction#H2277316\" class=\"medical medical_review\">&quot;Techniques for ripening the unfavorable cervix prior to induction&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>IAI is typically polymicrobial, often involving vaginal or enteric flora (<a href=\"image.htm?imageKey=OBGYN%2F107698\" class=\"graphic graphic_table graphicRef107698 \">table 2</a> and <a href=\"image.htm?imageKey=OBGYN%2F66106\" class=\"graphic graphic_table graphicRef66106 \">table 3</a>). Two-thirds of women with IAI have at least two isolates per specimen of amniotic fluid.</p><p>Regardless of gestational age, genital mycoplasmas (<em>Ureaplasma</em> and <em>Mycoplasma</em> species) are the most common isolates [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/26\" class=\"abstract_t\">26</a>]. Anaerobes (including <em>Gardnerella vaginalis</em>), enteric gram-negative bacilli, and group B <em>Streptococcus</em> are other frequent pathogens. Anaerobes appear to be more frequently involved in preterm IAI than term IAI [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Genital mycoplasmas are the most frequent organisms detected in cases of culture-confirmed chorioamnionitis and are highly prevalent (&gt;70 percent) in the lower genital tract. For this reason, some authors attribute their isolation from patients with IAI to contamination or colonization from the lower tract rather than a true infection. However, as data accrue, there is increasing support for their pathogenicity, including induction of a robust inflammatory response with clinical consequences for both mother and neonate [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/26,28\" class=\"abstract_t\">26,28</a>].</p><p class=\"headingAnchor\" id=\"H24364408\"><span class=\"h1\">CLINICAL FINDINGS</span></p><p class=\"headingAnchor\" id=\"H24368502\"><span class=\"h2\">Presentation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>IAI often occurs in women with premature rupture of membranes (PROM) but can occur with intact membranes, especially in laboring women. The key clinical findings, which are nonspecific, and their frequencies are as follows [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/14,15\" class=\"abstract_t\">14,15</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever (100 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maternal leukocytosis (variously defined as white blood cell count <span class=\"nowrap\">&gt;12,000/mm<sup>3</sup></span> or <span class=\"nowrap\">&gt;15,000/mm<sup>3</sup>)</span> (70 to 90 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maternal tachycardia <span class=\"nowrap\">&gt;100/min</span> (50 to 80 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fetal tachycardia <span class=\"nowrap\">&gt;160/min</span> (40 to 70 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uterine tenderness (4 to 25 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bacteremia (5 to 10 percent). Bacteremia is most common when IAI is associated with group B <em>Streptococcus</em> or <em>Escherichia coli</em> infection (bacteremia in 18 and 15 percent of cases, respectively).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Purulent or malodorous amniotic fluid.</p><p/><p>IAI may be subclinical, which by definition does not present with the above clinical findings. Subclinical infection may manifest as preterm labor with intact membranes or as preterm premature rupture of membranes (PPROM). Computerized analysis of the fetal heart rate may show reduced variability [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/29,30\" class=\"abstract_t\">29,30</a>].</p><p class=\"headingAnchor\" id=\"H24368317\"><span class=\"h2\">Potential maternal sequelae</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Dysfunctional labor</strong> &ndash; IAI is associated with an increased risk of labor abnormalities, which increase the risk for cesarean delivery, uterine atony, postpartum bleeding, and need for blood transfusion [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17,31,32\" class=\"abstract_t\">17,31,32</a>]. The type of bacteria appears to play a role: Women with persistent high-virulence organisms (eg, <em>Enterobacteriaceae</em>, Group A and B Streptococci, <em>Mycoplasma hominis</em>) in their amniotic fluid have more labor abnormalities than women with low-virulence organisms (<em>Ureaplasma urealyticum, </em>Lactobacilli<em>, Staphylococcus epidermidis</em>) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/33-37\" class=\"abstract_t\">33-37</a>]. The pathophysiologic mechanisms for labor abnormalities related to IAI are poorly understood and often complicated by other factors (eg, epidural anesthesia), but the link between IAI and both labor abnormalities and postpartum bleeding suggests dysfunctional myometrial contractility due to inflammation [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17,31,32,38\" class=\"abstract_t\">17,31,32,38</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Localized infection </strong>&ndash; Patients with IAI who undergo cesarean delivery, which is common, are at increased risk for wound infection, endomyometritis, septic pelvic thrombophlebitis, and pelvic abscess [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17,39\" class=\"abstract_t\">17,39</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sepsis</strong> &ndash; In a population-based study of maternal sepsis in the United States, 18 percent of cases were associated with IAI [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/40\" class=\"abstract_t\">40</a>]. The risk of life-threatening maternal sequelae, such as sepsis, coagulopathy, and adult respiratory distress syndrome related to IAI are low if treatment with broad-spectrum antibiotics is initiated. (See <a href=\"#H14\" class=\"local\">'Maternal management'</a> below.).</p><p/><p class=\"bulletIndent1\">An elevated&nbsp;lactic acid&nbsp;concentration&nbsp;can be a sign of&nbsp;sepsis and is associated with an adverse maternal outcome. Review of a database including 364 women with IAI showed that five developed severe sepsis (1.4 percent) and that it was difficult to identify these women upon initial presentation despite use of a modified obstetric early warning scoring system (<a href=\"image.htm?imageKey=OBGYN%2F104186\" class=\"graphic graphic_table graphicRef104186 \">table 4</a>) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/41\" class=\"abstract_t\">41</a>]. (See <a href=\"topic.htm?path=evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults\" class=\"medical medical_review\">&quot;Evaluation and management of suspected sepsis and septic shock in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H24368818\"><span class=\"h2\">Histology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The maternal immune response to IAI leads to neutrophilic inflammation of the chorioamnion (chorioamnionitis); the fetal immune response leads to neutrophilic inflammation of the umbilical cord (funisitis) <span class=\"nowrap\">and/or</span> fetal vessels in the chorionic plate (chorionic vasculitis). Chorioamnionitis is more common than funisitis: Funisitis is observed in up to 60 percent of cases of chorioamnionitis, while chorioamnionitis is observed in almost 100 percent of cases of funisitis [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/42\" class=\"abstract_t\">42</a>].</p><p>Microorganisms should be present in infection. The histologic diagnosis of chorioamnionitis may not correlate with clinical findings or microorganisms in the placenta, membranes, or amniotic fluid. In these cases, inflammatory changes in the membranes can result from noninfectious insults (hypoxic injury, trauma, meconium, allergens). Another reason for negative cultures is that cultures for fastidious organisms such as genital mycoplasmas, the most common organisms associated with chorioamnionitis, are not sensitive. Antibiotic therapy prior to delivery could also play a role. In one study, histologic and bacteriologic results were concordant in approximately 70 percent of the 376 examined placentas [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/43\" class=\"abstract_t\">43</a>]. When the diagnosis of chorioamnionitis was based on culture-positive amniotic fluid, sensitivity and specificity of histology were 83 to 100 percent and 23 to 52 percent, respectively [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/44\" class=\"abstract_t\">44</a>].</p><p>Histologic criteria for chorioamnionitis and funisitis are reviewed separately. (See <a href=\"topic.htm?path=the-placental-pathology-report#H9\" class=\"medical medical_review\">&quot;The placental pathology report&quot;, section on 'Acute or chronic chorioamnionitis'</a> and <a href=\"topic.htm?path=the-placental-pathology-report#H4\" class=\"medical medical_review\">&quot;The placental pathology report&quot;, section on 'Inflammation'</a>.)</p><p class=\"headingAnchor\" id=\"H3444251378\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most of the clinical findings associated with IAI are nonspecific (see <a href=\"#H24368502\" class=\"local\">'Presentation'</a> above). Intrapartum fever can be related to epidural anesthesia (see <a href=\"topic.htm?path=intrapartum-fever#H483714642\" class=\"medical medical_review\">&quot;Intrapartum fever&quot;, section on 'Use of epidural anesthesia'</a>). Maternal tachycardia during labor may be physiologic or related to pain, epidural anesthesia, or medications. Maternal leukocytosis occurs with both labor and antenatal corticosteroid therapy as well as infections other than IAI. Fetal tachycardia can be related to fetal hypoxemia, maternal fever of any etiology, or transplacental passage of some maternal medications.</p><p>Differential diagnosis of patients who present with clinical findings suggestive of IAI includes, but is not limited to:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Labor</strong> &ndash; Labor can be associated with fever (if the patient has an epidural anesthetic), maternal tachycardia, leukocytosis, and uterine tenderness.</p><p/><p class=\"bulletIndent1\">Diagnosis of clinical IAI is difficult in laboring patients with epidural anesthesia because fever is common in this setting and may be related to the anesthetic itself. In addition, epidural anesthesia masks uterine tenderness and may induce maternal or fetal tachycardia. Lastly, prolonged labor is a risk factor for both requesting epidural anesthesia and developing IAI. (See <a href=\"topic.htm?path=intrapartum-fever#H483714642\" class=\"medical medical_review\">&quot;Intrapartum fever&quot;, section on 'Use of epidural anesthesia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Abruptio placenta</strong> &ndash; Abruption can cause uterine tenderness and maternal tachycardia but is usually associated with vaginal bleeding and absence of fever (See <a href=\"topic.htm?path=placental-abruption-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Placental abruption: Clinical features and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other infections</strong> &ndash; Extrauterine infections associated with fever and abdominal pain (with or without labor) include pyelonephritis, influenza, appendicitis, and pneumonia. These infections can cause maternal tachycardia and leukocytosis, and fetal tachycardia; however, they can usually be differentiated from IAI by the clinical setting (eg, respiratory or gastrointestinal symptoms suggest an extrauterine source of fever) and laboratory tests (pyuria in urine obtained via a catheter suggests pyelonephritis). (See <a href=\"topic.htm?path=intrapartum-fever\" class=\"medical medical_review\">&quot;Intrapartum fever&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DIAGNOSIS OF INTRA-AMNIOTIC INFECTION</span></p><p class=\"headingAnchor\" id=\"H1457755771\"><span class=\"h2\">Diagnostic criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of IAI is commonly based on clinical findings. The key criterion is maternal fever, which is a manifestation of systemic inflammation; other criteria are insensitive. We agree with diagnostic criteria suggested by a National Institute of Child Health and Human Development Workshop expert panel (<a href=\"image.htm?imageKey=OBGYN%2F107670\" class=\"graphic graphic_table graphicRef107670 \">table 1</a>), and endorsed by the American College of Obstetricians and Gynecologists (ACOG) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/45\" class=\"abstract_t\">45</a>]. Of note, for treatment purposes, ACOG further suggests that patients with isolated fever &ge;39.0&deg;C (102.2&deg;F) should be managed as having suspected intra-amniotic infection.</p><p>A <strong>presumptive diagnosis</strong> of IAI (suspected triple I) can be made in women with:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Fever</strong> &ndash; &ge;39.0&deg;C [102.2&deg;F] <strong>or</strong> 38.0&deg;C [100.4&deg;F] to 38.9&deg;C [102.02&deg;F] on two occasions 30 minutes apart, without another clear source <strong>PLUS</strong> one or more of the following [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/1\" class=\"abstract_t\">1</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Baseline fetal heart rate &gt;160 <span class=\"nowrap\">beats/min</span> for &ge;10 minutes, excluding accelerations, decelerations, and periods of marked variability</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Maternal white cell count <span class=\"nowrap\">&gt;15,000/mm<sup>3</sup></span> in the absence of corticosteroids and ideally showing a left shift (bandemia)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Purulent-appearing fluid coming from the cervical os visualized by speculum examination</p><p/><p>The National Institute of Child Health and Human Development criteria de-emphasized use of maternal tachycardia (heart rate &gt;100 beats per minute) and fundal tenderness for clinical diagnosis, which had been used the past.</p><p>The presumptive diagnosis of IAI in febrile laboring patients is strengthened by the presence of risk factors for the disease, especially ruptured membranes, and by excluding other potential sources of fever. (See <a href=\"topic.htm?path=intrapartum-fever\" class=\"medical medical_review\">&quot;Intrapartum fever&quot;</a>.)</p><p>Measurement of C-reactive protein (CRP) in maternal serum is not part of the diagnostic evaluation. Meta-analyses concluded that an elevated maternal CRP level did not appear to be useful for early diagnosis of IAI or predicting neonatal sepsis, but was moderately predictive of histologic chorioamnionitis [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/46,47\" class=\"abstract_t\">46,47</a>]. Available studies were very heterogeneous, with a wide variety of sensitivity and specificity of CRP at various thresholds. We do not obtain blood cultures in women with IAI, except in rare atypical cases, such as septic shock. (See <a href=\"topic.htm?path=blood-cultures-for-the-detection-of-bacteremia#H5\" class=\"medical medical_review\">&quot;Blood cultures for the detection of bacteremia&quot;, section on 'Indications for cultures'</a>.)</p><p>A <strong>confirmed diagnosis</strong> of IAI can be made in women with:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>All of the above</strong> <strong>PLUS</strong> one or more of the following objective laboratory findings (see <a href=\"#H10\" class=\"local\">'Evaluation of amniotic fluid'</a> below) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/1\" class=\"abstract_t\">1</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Positive Gram stain of amniotic fluid </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Low glucose level in amniotic fluid</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Positive amniotic fluid culture</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>High white cell (WBC) count in amniotic fluid in the absence of a bloody tap</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Histopathologic evidence of infection or inflammation or both in the placenta, fetal membranes, or the umbilical cord vessels (funisitis)</p><p/><p>Laboratory studies should be performed on amniotic fluid obtained by amniocentesis. Histopathology is obtained after delivery.</p><p>The rationale for these criteria are the temperature and fetal heart rate criteria exceed the 90 to 95<sup>th</sup> percentile for normal pregnancies and the WBC count exceeds the 80<sup>th</sup> percentile. In addition, these thresholds are associated with higher rates of neonatal and maternal morbidity and, in preterm gestations, define a population whose amniotic fluid contains higher concentrations of organisms (&gt;100 colony forming <span class=\"nowrap\">units/mL</span> bacteria) and high-virulence isolates (group B <em>Streptococcus</em>, aerobic gram-negative rods, anaerobes, and <em>Mycoplasma hominis</em>).</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Evaluation of amniotic fluid</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A presumptive diagnosis of IAI is adequate for initiating maternal therapy in most cases. However, when the presumptive diagnosis of IAI is uncertain because of absence of typical clinical findings or overlap with other disorders, evaluation of amniotic fluid can confirm or exclude the diagnosis of IAI.</p><p>Culture of amniotic fluid remains the &quot;gold standard&quot; and most specific test for documentation of IAI but is limited by the fact that it may take days to obtain definitive results, which is too long to be clinically useful. Results from several other tests, including Gram stain, glucose concentration, WBC concentration, and leukocyte esterase level, can be obtained more rapidly. The majority of these tests have relatively low predictive value for a positive amniotic fluid culture and even lower ability to predict neonatal sepsis [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/48,49\" class=\"abstract_t\">48,49</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Gram stain</strong> is performed on an unspun specimen of amniotic fluid; centrifugation does not significantly improve the sensitivity of the technique. Twenty to 30 high-power fields should be examined. The presence of any bacteria and leukocytes (at least six leukocytes per high-power field) is suspicious for infection. In an individual patient-level meta-analysis based on two studies [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/50,51\" class=\"abstract_t\">50,51</a>] with a total of 288 women with preterm labor and intact membranes (11.8 percent with culture-confirmed IAI), sensitivity and specificity of positive Gram stain were 65 and 99 percent, respectively [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Glucose concentration</strong> is measured with an autoanalyzer (abnormal result &lt;15 <span class=\"nowrap\">mg/dL)</span>. In the individual patient-level meta-analysis discussed above, sensitivity and specificity of glucose &le;14 <span class=\"nowrap\">mg/dL</span> were 85 and 87 percent, respectively [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/52\" class=\"abstract_t\">52</a>]. A combination of positive Gram stain or glucose &le;14 <span class=\"nowrap\">mg/dL</span> afforded a sensitivity of 88 percent and specificity of 87 percent &ndash; not much different from a low glucose level alone.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>WBC concentration</strong> can be determined using a Coulter counter (abnormal result &gt;30 <span class=\"nowrap\">cells/mm<sup>3</sup>)</span>. In a study of 120 patients with preterm labor and intact membranes, sensitivity was 64 percent and specificity was 95 percent [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Leukocyte esterase activity</strong> can be evaluated with a urine dipstick reagent strip (eg, Chemstrip 9 Reagent Strips, an abnormal result is trace or greater). Sensitivity ranges from 85 to 91 percent; specificity ranges from 95 to 100 percent [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/53,54\" class=\"abstract_t\">53,54</a>].</p><p/><p>In patients with preterm labor, the combined result of positive Gram stain, positive leukocyte esterase, low glucose concentration, and elevated WBC concentration has sensitivity of 90 percent and specificity of 80 percent for predicting positive results of amniotic fluid culture. However, since the prevalence of IAI is relatively low (approximately 10 percent), this combination of tests has a false-positive rate of 67 percent; thus, the clinician should use caution in acting prior to obtaining culture results, particularly when the intervention involves delivery of an immature fetus. In addition, an elevated WBC concentration is less predictive of infection if the amniocentesis is traumatic (defined as amniotic fluid containing &ge;1000 red blood <span class=\"nowrap\">cells/mm3)</span> [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/55\" class=\"abstract_t\">55</a>].</p><p>Some clinicians perform amniocentesis to exclude subclinical IAI in patients with preterm labor or cervical insufficiency before attempts are made to prolong pregnancy. We do not routinely perform amniocentesis in patients with preterm labor or cervical insufficiency because of the poor predictive value of the combined test, the 48-hour delay in obtaining definitive culture results, and the lack of data proving that this approach reduces <span class=\"nowrap\">maternal/neonatal</span> morbidity. (See <a href=\"topic.htm?path=cervical-insufficiency\" class=\"medical medical_review\">&quot;Cervical insufficiency&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H775467\"><span class=\"h2\">Tests used in research studies</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Interleukin-6 (IL-6)</strong> &ndash; A high level of IL-6 in cervicovaginal fluid appears to be predictive of microbial invasion of the amniotic cavity in women with preterm labor and intact membranes [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/56\" class=\"abstract_t\">56</a>]. Elevated cytokine levels (eg, IL-6, matrix metalloproteinase [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/57,58\" class=\"abstract_t\">57,58</a>]) in amniotic fluid and fetal blood are associated with infection, preterm birth, and systemic fetal inflammatory syndrome [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/12,48\" class=\"abstract_t\">12,48</a>].</p><p/><p class=\"bulletIndent1\">Evidence of IAI by elevated IL-6 may be a more important prognostic factor for adverse outcomes than a positive amniotic fluid culture alone, which may represent only colonization. In a study of 305 women with preterm labor and intact membranes, median latency was similar in pregnancies with and without positive microbial culture [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/59\" class=\"abstract_t\">59</a>]. Pregnancies with and without positive microbial culture and IL-6 levels &lt;2.6 <span class=\"nowrap\">ng/mL</span> had longer median latency (23 to 25 days) compared with pregnancies with or without positive microbial culture but IL-6 &gt;11.3 <span class=\"nowrap\">ng/mL</span> (latency &lt;1 to 2 days) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/59\" class=\"abstract_t\">59</a>]. Regardless of microbial culture results, composite perinatal <span class=\"nowrap\">morbidity/mortality</span> rates were lower in pregnancies with IL-6 levels &lt;2.6 <span class=\"nowrap\">ng/mL</span> <span class=\"nowrap\">(morbidity/mortality</span> 21 to 25 percent) than in pregnancies with IL-6 levels &gt;11.3 <span class=\"nowrap\">ng/mL</span> <span class=\"nowrap\">(morbidity/mortality</span> 72 to 81 percent). The technical complexity of the assays, lack of standards across laboratories, and limited data on test characteristics currently restrict this testing to research settings in the United States. However, a rapid test has become available in some countries and provides results within 20 minutes [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Proteomic biomarkers</strong> &ndash; Evaluation of proteomic biomarkers in the amniotic fluid and maternal serum are under investigation in an attempt to identify unique proteins diagnostic of subclinical or early IAI [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/61-64\" class=\"abstract_t\">61-64</a>].</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">MATERNAL MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H3471316224\"><span class=\"h2\">Delivery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Women with IAI (including suspected or confirmed &quot;triple I&quot; (<a href=\"image.htm?imageKey=OBGYN%2F107670\" class=\"graphic graphic_table graphicRef107670 \">table 1</a>)) should be given antibiotics and delivered. Antimicrobial therapy provides bactericidal concentrations of antibiotics to the fetus, membranes, and amniotic fluid within one-half to one hour after infusion, but IAI can only be cured by delivery of the infected products of conception. The lack of efficacy of antibiotics alone may be because amniotic fluid bacteria can form biofilms, which are resistant to antibiotic treatment [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/8\" class=\"abstract_t\">8</a>].</p><p>We suggest prompt induction or augmentation of labor, as appropriate, with cesarean delivery reserved for standard obstetric indications. In women receiving antibiotics, there is no evidence that the duration of labor correlates with adverse neonatal outcome [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17,65\" class=\"abstract_t\">17,65</a>]; therefore, cesarean delivery should be reserved for standard obstetric indications. Cesarean delivery in the presence of IAI increases the risk of wound infection, endomyometritis, and venous thrombosis.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Antibiotic therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Broad-spectrum antibiotics should be given promptly following a diagnosis of IAI to initiate treatment of both the mother and fetus. We administer antibiotics to women with a presumptive diagnosis of IAI even if epidural-related fever cannot be excluded. Early initiation of antibiotic therapy may reduce the frequency and severity of neonatal infection [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/66-68\" class=\"abstract_t\">66-68</a>].</p><p class=\"headingAnchor\" id=\"H2987343931\"><span class=\"h3\">Intrapartum regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of broad spectrum parenteral antibiotics with coverage for beta-lactamase-producing aerobes and anaerobes is the preferred therapy of both IAI and postpartum endometritis. Our preference is:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin</a> 2 g intravenously every six hours PLUS</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">Gentamicin</a> 5 <span class=\"nowrap\">mg/kg</span> once daily </p><p/><p>A single daily <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> dose is equally or more effective and more convenient than thrice-daily dosing and safe when used intrapartum or postpartum [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/69,70\" class=\"abstract_t\">69,70</a>]. It does not result in toxic maternal levels (peak 18.2 <span class=\"nowrap\">microg/mL</span> and &lt;2 <span class=\"nowrap\">microg/mL</span> by 10 hours) and results in appropriate fetal serum levels (peak 6.9 <span class=\"nowrap\">microg/mL);</span> fetal levels are lower with standard dosing (1.5 <span class=\"nowrap\">mg/kg</span> every eight hours: fetal level 2.9 <span class=\"nowrap\">microg/mL)</span> [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/71\" class=\"abstract_t\">71</a>]. Routine monitoring of gentamicin levels is unnecessary for women who are healthy except for IAI. For women with renal insufficiency, we adjust the gentamicin dose with the assistance of a clinical pharmacist; serum levels and creatinine clearance are monitored to guide dosing. (See <a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">&quot;Dosing and administration of parenteral aminoglycosides&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2312899994\"><span class=\"h4\">Alternatives</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some reasonable alternative intravenous antibiotic regimens include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin</a> 2 g every six hours PLUS <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 1.5 <span class=\"nowrap\">mg/kg</span> every eight hours for patients with normal renal function. Some centers use a gentamicin load (eg, 2 <span class=\"nowrap\">mg/kg)</span> with thrice-daily dosing, but objective data to support its superiority are lacking.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ampicillin-and-sulbactam-drug-information\" class=\"drug drug_general\">Ampicillin-sulbactam</a> 3 g every six hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">Ticarcillin-clavulanate</a> 3.1 g every four hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefoxitin-drug-information\" class=\"drug drug_general\">Cefoxitin</a> 2 g every 8 hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cefotetan-drug-information\" class=\"drug drug_general\">Cefotetan</a> 2 g every 12 hours</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=piperacillin-and-tazobactam-sodium-drug-information\" class=\"drug drug_general\">Piperacillin-tazobactam</a> 3.375 g every 6 hours or 4.5 g every 8 hours.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">Ertapenem</a> 1 g every 24 hours</p><p/><p>There are few good comparative trials of antibiotic regimens on which to base treatment recommendations. In a systematic review [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/66\" class=\"abstract_t\">66</a>], there was no clear difference in the incidence of postpartum endometritis between women who received treatment with <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> alone versus those who received ampicillin, gentamicin, and <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> (relative risk 1.86, 95% CI 0.67-5.14, one trial, n = 133) and no randomized trials comparing other regimens.</p><p class=\"headingAnchor\" id=\"H512429280\"><span class=\"h3\">Postpartum regimens</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of antibiotic therapy after delivery has not been determined conclusively. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vaginal delivery</strong>, the author administers one additional dose of antibiotics, but believes discontinuing antibiotics is a reasonable alternative, given low quality evidence of available evidence. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cesarean delivery</strong>, in women with IAI undergoing cesarean delivery, anaerobic coverage should be added to the regimen used for vaginal delivery because anaerobes play a major role in complications associated with postcesarean endometritis. The addition of anaerobic coverage has reduced failure rates of postcesarean endometritis. Our preference is [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/70\" class=\"abstract_t\">70</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">Ampicillin</a> 2 g every six hours PLUS</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">Gentamicin</a> 5.0 <span class=\"nowrap\">mg/kg</span> once daily PLUS </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Either <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 900 mg <strong>or</strong> <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> 500 mg </p><p/><p class=\"bulletIndent1\">The author administers additional doses of the antibiotic regimen postpartum until the patient is afebrile and asymptomatic for at least 48 hours, but believes one additional dose only (particularly for non-obese patients) is a reasonable alternative, given low-quality of available evidence. </p><p/><p>These approaches are based on data from a few small randomized trials and observational studies of women treated for chorioamnionitis before delivery that compared the outcomes of women treated with no or one postpartum dose of antibiotics with the outcomes of those who received multiple postpartum antibiotic doses [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/66,72\" class=\"abstract_t\">66,72</a>]. In these trials, administration of multiple doses of antibiotics was not associated with a significant reduction in treatment failure (usually defined as persistent fever) compared with less intensive therapy. </p><p>Some clinicians continue the administration of antibiotics after delivery until the patient is afebrile and asymptomatic for at least 24 hours. This is a reasonable alternative approach, given the small number of subjects and postpartum febrile events in the available studies and differences among the studies in patient characteristics and treatment regimens. In one retrospective study, patients most likely to benefit from this approach were those who underwent cesarean delivery since they had a higher prevalence of persistent fever after delivery (15 versus 1 percent after vaginal delivery) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/72\" class=\"abstract_t\">72</a>]. </p><p>The American College of Obstetricians and Gynecologists (ACOG) committee opinion on IAI states that additional antibiotic doses are not required after vaginal delivery and at least one additional dose is indicated after cesarean delivery [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/45\" class=\"abstract_t\">45</a>]. </p><p>There is <strong>no</strong> evidence that oral antibiotics are beneficial after discontinuation of parenteral therapy [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/73\" class=\"abstract_t\">73</a>].</p><p>Treatment of women with postpartum endometritis is discussed separately. (See <a href=\"topic.htm?path=postpartum-endometritis\" class=\"medical medical_review\">&quot;Postpartum endometritis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1356849162\"><span class=\"h3\">Group B Streptococcus-positive women</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients receiving intrapartum <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> for group B <em>Streptococcus</em> (GBS) prophylaxis need broader antibiotic coverage if they develop IAI. An appropriate option is <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> and <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a>. </p><p class=\"headingAnchor\" id=\"H6031413\"><span class=\"h3\">Penicillin-allergic patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evidence-based data to guide the treatment of IAI in penicillin-allergic patients are lacking (see <a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">&quot;Penicillin allergy: Immediate reactions&quot;</a>). At our institution, we substitute <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> 1 g intravenously every 12 hours for <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> (ie, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 5 <span class=\"nowrap\">mg/kg</span> once daily plus vancomycin 1 g every 12 hours). </p><p><a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">Gentamicin</a> 5 <span class=\"nowrap\">mg/kg</span> once daily plus <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 900 mg intravenously every 8 hours is an acceptable alternative, unless the GBS coverage is indicated. In these cases, clindamycin should only be used if clindamycin-inducible resistance testing is negative. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention#H13\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;, section on 'Patients with penicillin allergy'</a>.) </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Fetal monitoring during labor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Use of continuous electronic fetal monitoring is appropriate in these patients to detect development of fetal compromise due to sequelae of IAI (villous edema, hyperthermic stress, fetal infection) or other factors. Fetal infection is not associated with a specific pattern of periodic fetal heart rate changes, except mild baseline tachycardia in some cases, which is a category II tracing. Management of category II tracings is reviewed separately. (See <a href=\"topic.htm?path=management-of-intrapartum-category-i-ii-and-iii-fetal-heart-rate-tracings\" class=\"medical medical_review\">&quot;Management of intrapartum category I, II, and III fetal heart rate tracings&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H24368953\"><span class=\"h2\">Antipyretics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of maternal fever and fetal acidosis conferred a 12.5 percent risk of neonatal encephalopathy (odds ratio [OR] 94, 95% CI 29-307) in one study, and each of these factors also appeared to have an independent effect (fever OR 8.1, 95% CI 3.5-18.6; neonatal acidosis OR 11.5, 95% CI 5.0-26.5) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/74\" class=\"abstract_t\">74</a>]. This observation supports the use of antipyretics in women with IAI. Reduction of intrapartum fever with antipyretics may also reduce fetal tachycardia, thereby avoiding the tendency to perform a cesarean delivery because of an abnormal fetal heart rate pattern. <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">Acetaminophen</a> is the preferred drug.</p><p class=\"headingAnchor\" id=\"H2369554605\"><span class=\"h2\">Postpartum care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Postpartum care is routine as IAI resolves after delivery in most women, particularly after vaginal delivery. Women with persistent fever <span class=\"nowrap\">and/or</span> pelvic pain should be evaluated for postpartum endometritis, wound infection after cesarean delivery, and, rarely, septic pelvic thrombophlebitis. (See <a href=\"topic.htm?path=postpartum-endometritis\" class=\"medical medical_review\">&quot;Postpartum endometritis&quot;</a> and <a href=\"topic.htm?path=cesarean-delivery-postoperative-issues#H6\" class=\"medical medical_review\">&quot;Cesarean delivery: Postoperative issues&quot;, section on 'Wound complications'</a> and <a href=\"topic.htm?path=septic-pelvic-thrombophlebitis\" class=\"medical medical_review\">&quot;Septic pelvic thrombophlebitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">FETAL AND NEONATAL OUTCOME</span></p><p class=\"headingAnchor\" id=\"H2795246259\"><span class=\"h2\">Adverse effects of intra-amniotic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adverse <span class=\"nowrap\">fetal/neonatal</span> outcomes include perinatal death, asphyxia, early-onset neonatal sepsis, septic shock, pneumonia, meningitis, intraventricular hemorrhage (IVH), cerebral white matter damage, and long-term disability including cerebral palsy, as well as morbidity related to preterm birth [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/75-80\" class=\"abstract_t\">75-80</a>]. Overall, IAI is associated with up to 40 percent of cases of early-onset neonatal sepsis [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/15\" class=\"abstract_t\">15</a>]. Preterm infants appear to have a higher rate of short-term complications from IAI than term infants; in one study: perinatal death (25 versus 6 percent in preterm and term infants), neonatal sepsis (28 versus 6 percent), pneumonia (20 versus 3 percent), grades 3 or 4 IVH (24 versus 8 percent), and respiratory distress (62 versus 35 percent) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/77\" class=\"abstract_t\">77</a>].</p><p>There is some evidence that fetal exposure to inflammation can induce interleukin-1 production, which enhances surfactant protein and lipid synthesis thereby promoting lung maturation; however, adverse effects on fetal lung development and outcome can also occur [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/81-83\" class=\"abstract_t\">81-83</a>]. These adverse effects include structural changes and alterations in growth factor expression and the immune system and possibly an increased risk for bronchopulmonary dysplasia. (See <a href=\"topic.htm?path=pathogenesis-and-clinical-features-of-bronchopulmonary-dysplasia#H14\" class=\"medical medical_review\">&quot;Pathogenesis and clinical features of bronchopulmonary dysplasia&quot;, section on 'Chorioamnionitis'</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Neurodevelopmental impairment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most studies have found that neurodevelopmental delay and cerebral palsy are potential long-term disabilities resulting from IAI, especially at or near term [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/84\" class=\"abstract_t\">84</a>], but also at extremely preterm gestational ages [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/85,86\" class=\"abstract_t\">85,86</a>]. In a 2010 meta-analysis of the relationship between chorioamnionitis and cerebral palsy, there were significant associations between cerebral palsy and both clinical chorioamnionitis (pooled odds ratio [OR] 2.42, 95% CI 1.52-3.84) and histologic chorioamnionitis (pooled OR 1.83, 95% CI 1.17-2.89) [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/84\" class=\"abstract_t\">84</a>]. However, this analysis was limited by many potential biases, such as differences in the definitions across studies, extent of blinding in determining exposure status, and whether the study controlled for potential confounders. A subsequent secondary analysis of data from 1574 newborns of women at high risk for preterm birth &lt;32 weeks enrolled in one clinical trial reported an association between neurocognitive deficits at two years of age and proven neonatal sepsis but not with clinical chorioamnionitis [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/87\" class=\"abstract_t\">87</a>]. The mean gestational age of these infants at birth was 29<sup><span class=\"nowrap\">3/7ths</span> </sup>weeks.</p><p>Fetal <span class=\"nowrap\">infection/inflammation</span> is likely a more important predictor of neonatal outcome than isolated maternal, amniotic fluid, or amniochorionic <span class=\"nowrap\">infection/inflammation</span> [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/85\" class=\"abstract_t\">85</a>]. The term systemic fetal inflammatory syndrome (also known as fetal inflammatory response syndrome) refers to the fetal immune response to intrauterine infection and the potential consequences of this response: preterm labor, fetal growth restriction, severe neonatal morbidity, brain injury, and development of chronic lung disease in the child [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/88-98\" class=\"abstract_t\">88-98</a>]. Funisitis and chorionic vasculitis appear to be the placental histologic manifestations of fetal inflammatory response syndrome and markers for adverse outcome [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/97,99-101\" class=\"abstract_t\">97,99-101</a>]. Laboratory findings include fetal plasma interleukin-6 (IL-6) concentration IL-6 &gt;11 <span class=\"nowrap\">pg/mL</span> [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/88,102\" class=\"abstract_t\">88,102</a>].</p><p>Neuroinflammation during the perinatal period can increase the risk of long-term neurologic and neuropsychiatric disease [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/103\" class=\"abstract_t\">103</a>]. High <span class=\"nowrap\">fetal/neonatal</span> levels of cytokines and chemokines, especially tumor necrosis factor [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/95\" class=\"abstract_t\">95</a>], appear to mediate <span class=\"nowrap\">fetal/neonatal</span> brain injury [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/90,93,95,104-106\" class=\"abstract_t\">90,93,95,104-106</a>]. These inflammatory substances can cause cerebral ischemia and damage, ultimately leading to intraventricular hemorrhage and periventricular leukomalacia. Intervention to prevent these outcomes is an active area of investigation. As an example, in a pilot study in rodents, intrapartum maternal treatment with an anti-inflammatory cytokine (eg, interleukin-10) prevented severe white matter damage in the pups of mothers with intrauterine infection [<a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/96\" class=\"abstract_t\">96</a>].</p><p>Neurodevelopmental impairment associated with IAI may involve multiple factors, including asphyxia and toxic injury by bacterial products.</p><p class=\"headingAnchor\" id=\"H953598879\"><span class=\"h2\">Newborn evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(See <a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants#H12\" class=\"medical medical_review\">&quot;Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants&quot;, section on 'Evaluation and initial management'</a>.)</p><p class=\"headingAnchor\" id=\"H24372776\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The main strategy to prevent IAI is administration of prophylactic antibiotics to women with preterm premature rupture of membranes (PPROM), which reduces the incidence of clinical chorioamnionitis, prolongs latency, and improves neonatal outcomes. The evidence for this approach is reviewed separately. (See <a href=\"topic.htm?path=preterm-prelabor-rupture-of-membranes#H17\" class=\"medical medical_review\">&quot;Preterm prelabor rupture of membranes&quot;, section on 'Prophylactic antibiotic therapy'</a>.) </p><p>For term PROM, we prefer delivery to expectant management with antibiotic prophylaxis. (See <a href=\"topic.htm?path=management-of-prelabor-rupture-of-the-fetal-membranes-at-term#H7\" class=\"medical medical_review\">&quot;Management of prelabor rupture of the fetal membranes at term&quot;, section on 'Antibiotic prophylaxis'</a>.)</p><p>Attention to modifiable risk factors may also reduce the incidence of IAI. Modifiable risk factors that pertain to the health care provider include conduct of labor (eg, minimizing the number of vaginal examinations) and use of prophylactic antibiotics in women with group B <em>Streptococcus</em> colonization. (See <a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">&quot;Neonatal group B streptococcal disease: Prevention&quot;</a>.)</p><p>Modifiable risk factors that the patient can control include avoidance of tobacco and alcohol. (See <a href=\"#H5\" class=\"local\">'Risk factors'</a> above.)</p><p class=\"headingAnchor\" id=\"H781998789\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Group B streptococcal infection in pregnant women and neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intra-amniotic infection (IAI, also called chorioamnionitis) refers to infection of the amniotic fluid, membranes, placenta, umbilical cord, <span class=\"nowrap\">and/or</span> decidua. It may be subgrouped as clinical (overt) or subclinical infection, or as histologic chorioamnionitis (which may be noninfectious). In 2015, a National Institute of Child Health and Human Development Workshop expert panel discouraged use of the term &quot;chorioamnionitis&quot; and recommended use of the term &quot;intrauterine infection or inflammation or both (triple I).&quot; (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H24368818\" class=\"local\">'Histology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>IAI is polymicrobial (<a href=\"image.htm?imageKey=OBGYN%2F66106\" class=\"graphic graphic_table graphicRef66106 \">table 3</a>) and usually results from migration of cervicovaginal flora through the cervical canal in women with ruptured membranes. Other causes include transplacental infection associated with bacteremia and bacterial contamination during invasive procedures. (See <a href=\"#H6\" class=\"local\">'Microbiology'</a> above and <a href=\"#H24363502\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A <strong>presumptive diagnosis</strong> of IAI can be made in women with fever (&ge;39.0&deg;C [102.2&deg;F] or 38.0&deg;C [100.4&deg;F] to 38.9&deg;C [102.02&deg;F] on two occasions, 30 minutes apart) without another clear source and one or more of the following (see <a href=\"#H7\" class=\"local\">'Diagnosis of intra-amniotic infection'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Baseline fetal heart rate &gt;160 <span class=\"nowrap\">beats/min</span> for &ge;10 minutes, excluding accelerations, decelerations, and periods of marked variability</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Maternal white cell count <span class=\"nowrap\">&gt;15,000/mm<sup>3</sup></span> in the absence of corticosteroids and ideally showing a left shift (bandemia)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Purulent-appearing fluid coming from the cervical os visualized by speculum examination</p><p/><p class=\"bulletIndent1\">A <strong>confirmed diagnosis</strong> of IAI can be made in women with all of the above and one or more of the following objective laboratory findings:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Amniotic fluid: positive Gram stain <span class=\"nowrap\">and/or</span> culture, low glucose concentration, or high white cell count</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Histopathologic evidence of infection or inflammation or both in the placenta, fetal membranes, or the umbilical cord vessels (funisitis)</p><p/><p class=\"bulletIndent1\">The National Institute of Child Health and Human Development have deemphasized use of maternal tachycardia and fundal tenderness for clinical diagnosis because these findings are nonspecific, and tenderness can be masked by neuraxial anesthesia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to maternal infectious complications (eg, postpartum endometritis), IAI may impair myometrial contractility, which can result in labor abnormalities, need for cesarean delivery, uterine atony, and postpartum hemorrhage. Cesarean delivery in the presence of IAI increases the risk of wound infection, endomyometritis, septic pelvic thrombophlebitis, and pelvic abscess. (See <a href=\"#H24368317\" class=\"local\">'Potential maternal sequelae'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Broad-spectrum antibiotics should be started as soon as a presumed diagnosis is made and continued through delivery to minimize maternal and fetal morbidity. Our preference is <a href=\"topic.htm?path=ampicillin-drug-information\" class=\"drug drug_general\">ampicillin</a> 2 g intravenously every six hours plus <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 5 <span class=\"nowrap\">mg/kg</span> once daily. <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> 900 mg or <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> 500 mg intravenously is added to this regimen to reduce postsurgical infections related to anaerobes in patients undergoing cesarean delivery. </p><p/><p class=\"bulletIndent1\">After vaginal delivery, the author administers one additional dose of antibiotics, but believes discontinuing antibiotics is a reasonable alternative.</p><p/><p class=\"bulletIndent1\">After cesarean delivery, the author administers one additional dose of antibiotics, but believes a longer duration of therapy (until the patient is afebrile and asymptomatic for at least 24 hours) is a reasonable alternative, especially in patients with other risk factors for postcesarean infection, such as obesity. (See <a href=\"#H15\" class=\"local\">'Antibiotic therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>IAI cannot be cured without delivery. We suggest prompt induction or augmentation of labor, as appropriate, with cesarean delivery reserved for standard obstetric indications (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Immediate (cesarean) delivery in the presence of reassuring intrapartum fetal testing, adequate progress of labor, and administration of antibiotics does not improve neonatal or maternal outcome. (See <a href=\"#H3471316224\" class=\"local\">'Delivery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adverse neonatal outcomes associated with IAI include perinatal death, asphyxia, early-onset neonatal sepsis, septic shock, pneumonia, meningitis, intraventricular hemorrhage, cerebral white matter damage, and long-term neurodevelopmental disability including cerebral palsy, as well as morbidity related to preterm birth. (See <a href=\"#H18\" class=\"local\">'Fetal and neonatal outcome'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/1\" class=\"nounderline abstract_t\">Higgins RD, Saade G, Polin RA, et al. Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop. Obstet Gynecol 2016; 127:426.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/2\" class=\"nounderline abstract_t\">Barth WH Jr. Lost in Translation: The Changing Language of Our Specialty. Obstet Gynecol 2016; 127:423.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/3\" class=\"nounderline abstract_t\">Park CW, Moon KC, Park JS, et al. The involvement of human amnion in histologic chorioamnionitis is an indicator that a fetal and an intra-amniotic inflammatory response is more likely and severe: clinical implications. Placenta 2009; 30:56.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/4\" class=\"nounderline abstract_t\">Kjaergaard N, Hein M, Hyttel L, et al. Antibacterial properties of human amnion and chorion in vitro. Eur J Obstet Gynecol Reprod Biol 2001; 94:224.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/5\" class=\"nounderline abstract_t\">Stock SJ, Kelly RW, Riley SC, Calder AA. Natural antimicrobial production by the amnion. Am J Obstet Gynecol 2007; 196:255.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/6\" class=\"nounderline abstract_t\">Kim YM, Romero R, Chaiworapongsa T, et al. Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol 2004; 191:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/7\" class=\"nounderline abstract_t\">Abrahams VM, Potter JA, Bhat G, et al. Bacterial modulation of human fetal membrane Toll-like receptor expression. Am J Reprod Immunol 2013; 69:33.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/8\" class=\"nounderline abstract_t\">Kim CJ, Romero R, Chaemsaithong P, et al. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol 2015; 213:S29.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/9\" class=\"nounderline abstract_t\">Lieberman E, Lang J, Richardson DK, et al. Intrapartum maternal fever and neonatal outcome. Pediatrics 2000; 105:8.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/10\" class=\"nounderline abstract_t\">Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamniotic infection: a prospective epidemiologic study. Am J Obstet Gynecol 1989; 161:562.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/11\" class=\"nounderline abstract_t\">Frigoletto FD Jr, Lieberman E, Lang JM, et al. A clinical trial of active management of labor. N Engl J Med 1995; 333:745.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/12\" class=\"nounderline abstract_t\">Yoon BH, Romero R, Moon JB, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001; 185:1130.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/13\" class=\"nounderline abstract_t\">Kenyon S, Boulvain M, Neilson J. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2003; :CD001058.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/14\" class=\"nounderline abstract_t\">Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993; 36:795.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/15\" class=\"nounderline abstract_t\">Tita AT, Andrews WW. Diagnosis and management of clinical chorioamnionitis. Clin Perinatol 2010; 37:339.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/16\" class=\"nounderline abstract_t\">Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol 1991; 164:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/17\" class=\"nounderline abstract_t\">Rouse DJ, Landon M, Leveno KJ, et al. The Maternal-Fetal Medicine Units cesarean registry: chorioamnionitis at term and its duration-relationship to outcomes. Am J Obstet Gynecol 2004; 191:211.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/18\" class=\"nounderline abstract_t\">Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol 1997; 177:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/19\" class=\"nounderline abstract_t\">Newton ER, Prihoda TJ, Gibbs RS. Logistic regression analysis of risk factors for intra-amniotic infection. Obstet Gynecol 1989; 73:571.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/20\" class=\"nounderline abstract_t\">Tran SH, Caughey AB, Musci TJ. Meconium-stained amniotic fluid is associated with puerperal infections. Am J Obstet Gynecol 2003; 189:746.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/21\" class=\"nounderline abstract_t\">Cheng YW, Delaney SS, Hopkins LM, Caughey AB. The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor. Am J Obstet Gynecol 2009; 201:477.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/22\" class=\"nounderline abstract_t\">Park HS, Romero R, Lee SM, et al. Histologic chorioamnionitis is more common after spontaneous labor than after induced labor at term. Placenta 2010; 31:792.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/23\" class=\"nounderline abstract_t\">Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol 1996; 175:304.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/24\" class=\"nounderline abstract_t\">Cohen-Cline HN, Kahn TR, Hutter CM. A population-based study of the risk of repeat clinical chorioamnionitis in Washington State, 1989-2008. Am J Obstet Gynecol 2012; 207:473.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/25\" class=\"nounderline abstract_t\">Cahill AG, Duffy CR, Odibo AO, et al. Number of cervical examinations and risk of intrapartum maternal fever. Obstet Gynecol 2012; 119:1096.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/26\" class=\"nounderline abstract_t\">Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18:757.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/27\" class=\"nounderline abstract_t\">Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis 1988; 157:113.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/28\" class=\"nounderline abstract_t\">Yoon BH, Romero R, Park JS, et al. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol 1998; 179:1254.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/29\" class=\"nounderline abstract_t\">Buscicchio G, Giannubilo SR, Bezzeccheri V, et al. Computerized analysis of the fetal heart rate in pregnancies complicated by preterm premature rupture of membranes (pPROM). J Matern Fetal Neonatal Med 2006; 19:39.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/30\" class=\"nounderline abstract_t\">Vandenbroucke L, Doyen M, Le Lous M, et al. Chorioamnionitis following preterm premature rupture of membranes and fetal heart rate variability. PLoS One 2017; 12:e0184924.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/31\" class=\"nounderline abstract_t\">Mark SP, Croughan-Minihane MS, Kilpatrick SJ. Chorioamnionitis and uterine function. Obstet Gynecol 2000; 95:909.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/32\" class=\"nounderline abstract_t\">Satin AJ, Maberry MC, Leveno KJ, et al. Chorioamnionitis: a harbinger of dystocia. Obstet Gynecol 1992; 79:913.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/33\" class=\"nounderline abstract_t\">Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term. J Infect Dis 1982; 145:1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/34\" class=\"nounderline abstract_t\">Silver RK, Gibbs RS, Castillo M. Effect of amniotic fluid bacteria on the course of labor in nulliparous women at term. Obstet Gynecol 1986; 68:587.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/35\" class=\"nounderline abstract_t\">Blanco JD, Gibbs RS, Malherbe H, et al. A controlled study of genital mycoplasmas in amniotic fluid from patients with intra-amniotic infection. J Infect Dis 1983; 147:650.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/36\" class=\"nounderline abstract_t\">Gibbs RS, Blanco JD, St Clair PJ, Castaneda YS. Mycoplasma hominis and intrauterine infection in late pregnancy. Sex Transm Dis 1983; 10:303.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/37\" class=\"nounderline abstract_t\">Gibbs RS, Blanco JD, Lipscomb K, St Clair PJ. Asymptomatic parturient women with high-virulence bacteria in the amniotic fluid. Am J Obstet Gynecol 1985; 152:650.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/38\" class=\"nounderline abstract_t\">Newton ER, Schroeder BC, Knape KG, Bennett BL. Epidural analgesia and uterine function. Obstet Gynecol 1995; 85:749.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/39\" class=\"nounderline abstract_t\">Hauth JC, Gilstrap LC 3rd, Hankins GD, Connor KD. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985; 66:59.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/40\" class=\"nounderline abstract_t\">Al-Ostad G, Kezouh A, Spence AR, Abenhaim HA. Incidence and risk factors of sepsis mortality in labor, delivery and after birth: population-based study in the USA. J Obstet Gynaecol Res 2015; 41:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/41\" class=\"nounderline abstract_t\">Edwards SE, Grobman WA, Lappen JR, et al. Modified obstetric early warning scoring systems (MOEWS): validating the diagnostic performance for severe sepsis in women with chorioamnionitis. Am J Obstet Gynecol 2015; 212:536.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/42\" class=\"nounderline abstract_t\">Holcroft CJ, Askin FB, Patra A, et al. Are histopathologic chorioamnionitis and funisitis associated with metabolic acidosis in the preterm fetus? Am J Obstet Gynecol 2004; 191:2010.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/43\" class=\"nounderline abstract_t\">Queiros da Mota V, Prodhom G, Yan P, et al. Correlation between placental bacterial culture results and histological chorioamnionitis: a prospective study on 376 placentas. J Clin Pathol 2013; 66:243.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/44\" class=\"nounderline abstract_t\">Pettker CM, Buhimschi IA, Magloire LK, et al. Value of placental microbial evaluation in diagnosing intra-amniotic infection. Obstet Gynecol 2007; 109:739.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/45\" class=\"nounderline abstract_t\">Committee on Obstetric Practice. Committee Opinion No. 712: Intrapartum Management of Intraamniotic Infection. Obstet Gynecol 2017; 130:e95.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/46\" class=\"nounderline abstract_t\">van de Laar R, van der Ham DP, Oei SG, et al. Accuracy of C-reactive protein determination in predicting chorioamnionitis and neonatal infection in pregnant women with premature rupture of membranes: a systematic review. Eur J Obstet Gynecol Reprod Biol 2009; 147:124.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/47\" class=\"nounderline abstract_t\">Trochez-Martinez RD, Smith P, Lamont RF. Use of C-reactive protein as a predictor of chorioamnionitis in preterm prelabour rupture of membranes: a systematic review. BJOG 2007; 114:796.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/48\" class=\"nounderline abstract_t\">Gomez R, Ghezzi F, Romero R, et al. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol 1995; 22:281.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/49\" class=\"nounderline abstract_t\">Gauthier DW, Meyer WJ. Comparison of gram stain, leukocyte esterase activity, and amniotic fluid glucose concentration in predicting amniotic fluid culture results in preterm premature rupture of membranes. Am J Obstet Gynecol 1992; 167:1092.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/50\" class=\"nounderline abstract_t\">Romero R, Yoon BH, Mazor M, et al. The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. Am J Obstet Gynecol 1993; 169:805.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/51\" class=\"nounderline abstract_t\">Romero R, Jimenez C, Lohda AK, et al. Amniotic fluid glucose concentration: a rapid and simple method for the detection of intraamniotic infection in preterm labor. Am J Obstet Gynecol 1990; 163:968.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/52\" class=\"nounderline abstract_t\">Lisonkova S, Sabr Y, Joseph KS. Diagnosis of subclinical amniotic fluid infection prior to rescue cerclage using gram stain and glucose tests: an individual patient meta-analysis. J Obstet Gynaecol Can 2014; 36:116.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/53\" class=\"nounderline abstract_t\">Riggs JW, Blanco JD. Pathophysiology, diagnosis, and management of intraamniotic infection. Semin Perinatol 1998; 22:251.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/54\" class=\"nounderline abstract_t\">Hoskins IA, Marks F, Ordorica SA, Young BK. Leukocyte esterase activity in amniotic fluid: normal values during pregnancy. Am J Perinatol 1990; 7:130.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/55\" class=\"nounderline abstract_t\">Abdel-Razeq SS, Buhimschi IA, Bahtiyar MO, et al. Interpretation of amniotic fluid white blood cell count in &quot;bloody tap&quot; amniocenteses in women with symptoms of preterm labor. Obstet Gynecol 2010; 116:344.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/56\" class=\"nounderline abstract_t\">Combs CA, Garite TJ, Lapidus JA, et al. Detection of microbial invasion of the amniotic cavity by analysis of cervicovaginal proteins in women with preterm labor and intact membranes. Am J Obstet Gynecol 2015; 212:482.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/57\" class=\"nounderline abstract_t\">Romero R, Yoon BH, Mazor M, et al. A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. Am J Obstet Gynecol 1993; 169:839.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/58\" class=\"nounderline abstract_t\">Kim KW, Romero R, Park HS, et al. A rapid matrix metalloproteinase-8 bedside test for the detection of intraamniotic inflammation in women with preterm premature rupture of membranes. Am J Obstet Gynecol 2007; 197:292.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/59\" class=\"nounderline abstract_t\">Combs CA, Gravett M, Garite TJ, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. Am J Obstet Gynecol 2014; 210:125.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/60\" class=\"nounderline abstract_t\">Kacerovsky M, Musilova I, Hornychova H, et al. Bedside assessment of amniotic fluid interleukin-6 in preterm prelabor rupture of membranes. Am J Obstet Gynecol 2014; 211:385.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/61\" class=\"nounderline abstract_t\">Gravett MG, Novy MJ, Rosenfeld RG, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004; 292:462.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/62\" class=\"nounderline abstract_t\">Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 2005; 112:173.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/63\" class=\"nounderline abstract_t\">Buhimschi IA, Zambrano E, Pettker CM, et al. Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol 2008; 111:403.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/64\" class=\"nounderline abstract_t\">Hitti J, Lapidus JA, Lu X, et al. Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am J Obstet Gynecol 2010; 203:32.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/65\" class=\"nounderline abstract_t\">Gilstrap LC 3rd, Cox SM. Acute chorioamnionitis. Obstet Gynecol Clin North Am 1989; 16:373.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/66\" class=\"nounderline abstract_t\">Chapman E, Reveiz L, Illanes E, Bonfill Cosp X. Antibiotic regimens for management of intra-amniotic infection. Cochrane Database Syst Rev 2014; :CD010976.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/67\" class=\"nounderline abstract_t\">Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2013; :CD001058.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/68\" class=\"nounderline abstract_t\">Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2014; :CD007467.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/69\" class=\"nounderline abstract_t\">Lyell DJ, Pullen K, Fuh K, et al. Daily compared with 8-hour gentamicin for the treatment of intrapartum chorioamnionitis: a randomized controlled trial. Obstet Gynecol 2010; 115:344.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/70\" class=\"nounderline abstract_t\">Mackeen AD, Packard RE, Ota E, Speer L. Antibiotic regimens for postpartum endometritis. Cochrane Database Syst Rev 2015; :CD001067.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/71\" class=\"nounderline abstract_t\">Locksmith GJ, Chin A, Vu T, et al. High compared with standard gentamicin dosing for chorioamnionitis: a comparison of maternal and fetal serum drug levels. Obstet Gynecol 2005; 105:473.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/72\" class=\"nounderline abstract_t\">Black LP, Hinson L, Duff P. Limited course of antibiotic treatment for chorioamnionitis. Obstet Gynecol 2012; 119:1102.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/73\" class=\"nounderline abstract_t\">Dinsmoor MJ, Newton ER, Gibbs RS. A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis. Obstet Gynecol 1991; 77:60.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/74\" class=\"nounderline abstract_t\">Impey LW, Greenwood CE, Black RS, et al. The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy. Am J Obstet Gynecol 2008; 198:49.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/75\" class=\"nounderline abstract_t\">Yoder PR, Gibbs RS, Blanco JD, et al. A prospective, controlled study of maternal and perinatal outcome after intra-amniotic infection at term. Am J Obstet Gynecol 1983; 145:695.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/76\" class=\"nounderline abstract_t\">Alexander JM, McIntire DM, Leveno KJ. Chorioamnionitis and the prognosis for term infants. Obstet Gynecol 1999; 94:274.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/77\" class=\"nounderline abstract_t\">Morales WJ, Washington SR 3rd, Lazar AJ. The effect of chorioamnionitis on perinatal outcome in preterm gestation. J Perinatol 1987; 7:105.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/78\" class=\"nounderline abstract_t\">Lau J, Magee F, Qiu Z, et al. Chorioamnionitis with a fetal inflammatory response is associated with higher neonatal mortality, morbidity, and resource use than chorioamnionitis displaying a maternal inflammatory response only. Am J Obstet Gynecol 2005; 193:708.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/79\" class=\"nounderline abstract_t\">Aziz N, Cheng YW, Caughey AB. Neonatal outcomes in the setting of preterm premature rupture of membranes complicated by chorioamnionitis. J Matern Fetal Neonatal Med 2009; 22:780.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/80\" class=\"nounderline abstract_t\">Ramsey PS, Lieman JM, Brumfield CG, Carlo W. Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture of membranes. Am J Obstet Gynecol 2005; 192:1162.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/81\" class=\"nounderline abstract_t\">Kunzmann S, Collins JJ, Kuypers E, Kramer BW. Thrown off balance: the effect of antenatal inflammation on the developing lung and immune system. Am J Obstet Gynecol 2013; 208:429.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/82\" class=\"nounderline abstract_t\">Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97:210.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/83\" class=\"nounderline abstract_t\">Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2012; 97:F8.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/84\" class=\"nounderline abstract_t\">Shatrov JG, Birch SC, Lam LT, et al. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet Gynecol 2010; 116:387.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/85\" class=\"nounderline abstract_t\">Pappas A, Kendrick DE, Shankaran S, et al. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA Pediatr 2014; 168:137.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/86\" class=\"nounderline abstract_t\">Leviton A, Allred EN, Kuban KC, et al. Microbiologic and histologic characteristics of the extremely preterm infant's placenta predict white matter damage and later cerebral palsy. the ELGAN study. Pediatr Res 2010; 67:95.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/87\" class=\"nounderline abstract_t\">Vander Haar E, Gyamfi-Bannerman C. Chorioamnionitis and Neurocognitive Development at Age 2 Years. Obstet Gynecol 2016; 127:437.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/88\" class=\"nounderline abstract_t\">Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179:194.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/89\" class=\"nounderline abstract_t\">Perlman JM. White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Early Hum Dev 1998; 53:99.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/90\" class=\"nounderline abstract_t\">Leviton A, Paneth N, Reuss ML, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res 1999; 46:566.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/91\" class=\"nounderline abstract_t\">Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. I. Univariate analysis of risks. Am J Dis Child 1985; 139:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/92\" class=\"nounderline abstract_t\">Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000; 284:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/93\" class=\"nounderline abstract_t\">Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177:19.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/94\" class=\"nounderline abstract_t\">Williams MC, O'Brien WF, Nelson RN, Spellacy WN. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants. Am J Obstet Gynecol 2000; 183:1094.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/95\" class=\"nounderline abstract_t\">Kadhim H, Tabarki B, Verellen G, et al. Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology 2001; 56:1278.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/96\" class=\"nounderline abstract_t\">Rodts-Palenik S, Wyatt-Ashmead J, Pang Y, et al. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Am J Obstet Gynecol 2004; 191:1387.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/97\" class=\"nounderline abstract_t\">Pacora P, Chaiworapongsa T, Maymon E, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med 2002; 11:18.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/98\" class=\"nounderline abstract_t\">Hofer N, Kothari R, Morris N, et al. The fetal inflammatory response syndrome is a risk factor for morbidity in preterm neonates. Am J Obstet Gynecol 2013; 209:542.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/99\" class=\"nounderline abstract_t\">Yoon BH, Romero R, Park JS, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000; 183:1124.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/100\" class=\"nounderline abstract_t\">Jobe AH. Antenatal associations with lung maturation and infection. J Perinatol 2005; 25 Suppl 2:S31.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/101\" class=\"nounderline abstract_t\">Mittendorf R, Montag AG, MacMillan W, et al. Components of the systemic fetal inflammatory response syndrome as predictors of impaired neurologic outcomes in children. Am J Obstet Gynecol 2003; 188:1438.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/102\" class=\"nounderline abstract_t\">Romero R, Gomez R, Ghezzi F, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol 1998; 179:186.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/103\" class=\"nounderline abstract_t\">Hagberg H, Mallard C, Ferriero DM, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol 2015; 11:192.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/104\" class=\"nounderline abstract_t\">Debillon T, Gras-Leguen C, V&eacute;rielle V, et al. Intrauterine infection induces programmed cell death in rabbit periventricular white matter. Pediatr Res 2000; 47:736.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/105\" class=\"nounderline abstract_t\">Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42:1.</a></li><li><a href=\"https://www.uptodate.com/contents/intra-amniotic-infection-clinical-chorioamnionitis-or-triple-i/abstract/106\" class=\"nounderline abstract_t\">Lu HY, Zhang Q, Wang QX, Lu JY. Contribution of Histologic Chorioamnionitis and Fetal Inflammatory Response Syndrome to Increased Risk of Brain Injury in Infants With Preterm Premature Rupture of Membranes. Pediatr Neurol 2016; 61:94.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6762 Version 49.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H24363502\" id=\"outline-link-H24363502\">PATHOGENESIS</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">INCIDENCE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">RISK FACTORS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">MICROBIOLOGY</a></li><li><a href=\"#H24364408\" id=\"outline-link-H24364408\">CLINICAL FINDINGS</a><ul><li><a href=\"#H24368502\" id=\"outline-link-H24368502\">Presentation</a></li><li><a href=\"#H24368317\" id=\"outline-link-H24368317\">Potential maternal sequelae</a></li><li><a href=\"#H24368818\" id=\"outline-link-H24368818\">Histology</a></li><li><a href=\"#H3444251378\" id=\"outline-link-H3444251378\">Differential diagnosis</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">DIAGNOSIS OF INTRA-AMNIOTIC INFECTION</a><ul><li><a href=\"#H1457755771\" id=\"outline-link-H1457755771\">Diagnostic criteria</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Evaluation of amniotic fluid</a></li><li><a href=\"#H775467\" id=\"outline-link-H775467\">Tests used in research studies</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">MATERNAL MANAGEMENT</a><ul><li><a href=\"#H3471316224\" id=\"outline-link-H3471316224\">Delivery</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Antibiotic therapy</a><ul><li><a href=\"#H2987343931\" id=\"outline-link-H2987343931\">- Intrapartum regimen</a><ul><li><a href=\"#H2312899994\" id=\"outline-link-H2312899994\">Alternatives</a></li></ul></li><li><a href=\"#H512429280\" id=\"outline-link-H512429280\">- Postpartum regimens</a></li><li><a href=\"#H1356849162\" id=\"outline-link-H1356849162\">- Group B Streptococcus-positive women</a></li><li><a href=\"#H6031413\" id=\"outline-link-H6031413\">- Penicillin-allergic patients</a></li></ul></li><li><a href=\"#H17\" id=\"outline-link-H17\">Fetal monitoring during labor</a></li><li><a href=\"#H24368953\" id=\"outline-link-H24368953\">Antipyretics</a></li><li><a href=\"#H2369554605\" id=\"outline-link-H2369554605\">Postpartum care</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">FETAL AND NEONATAL OUTCOME</a><ul><li><a href=\"#H2795246259\" id=\"outline-link-H2795246259\">Adverse effects of intra-amniotic infection</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Neurodevelopmental impairment</a></li><li><a href=\"#H953598879\" id=\"outline-link-H953598879\">Newborn evaluation</a></li></ul></li><li><a href=\"#H24372776\" id=\"outline-link-H24372776\">PREVENTION</a></li><li><a href=\"#H781998789\" id=\"outline-link-H781998789\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"OBGYN/6762|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=OBGYN/107670\" class=\"graphic graphic_table\">- Classification of triple I</a></li><li><a href=\"image.htm?imageKey=OBGYN/107698\" class=\"graphic graphic_table\">- Microbiology amniotic fluid in preterm labor or chorioamnionitis</a></li><li><a href=\"image.htm?imageKey=OBGYN/66106\" class=\"graphic graphic_table\">- Microbiology of IAI</a></li><li><a href=\"image.htm?imageKey=OBGYN/104186\" class=\"graphic graphic_table\">- Maternal early warning criteria</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=blood-cultures-for-the-detection-of-bacteremia\" class=\"medical medical_review\">Blood cultures for the detection of bacteremia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cervical-insufficiency\" class=\"medical medical_review\">Cervical insufficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cesarean-delivery-postoperative-issues\" class=\"medical medical_review\">Cesarean delivery: Postoperative issues</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dosing-and-administration-of-parenteral-aminoglycosides\" class=\"medical medical_review\">Dosing and administration of parenteral aminoglycosides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-suspected-sepsis-and-septic-shock-in-adults\" class=\"medical medical_review\">Evaluation and management of suspected sepsis and septic shock in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intrapartum-fever\" class=\"medical medical_review\">Intrapartum fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-intrapartum-category-i-ii-and-iii-fetal-heart-rate-tracings\" class=\"medical medical_review\">Management of intrapartum category I, II, and III fetal heart rate tracings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-prelabor-rupture-of-the-fetal-membranes-at-term\" class=\"medical medical_review\">Management of prelabor rupture of the fetal membranes at term</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-group-b-streptococcal-disease-prevention\" class=\"medical medical_review\">Neonatal group B streptococcal disease: Prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-clinical-features-of-bronchopulmonary-dysplasia\" class=\"medical medical_review\">Pathogenesis and clinical features of bronchopulmonary dysplasia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-spontaneous-preterm-birth\" class=\"medical medical_review\">Pathogenesis of spontaneous preterm birth</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=penicillin-allergy-immediate-reactions\" class=\"medical medical_review\">Penicillin allergy: Immediate reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=placental-abruption-clinical-features-and-diagnosis\" class=\"medical medical_review\">Placental abruption: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postpartum-endometritis\" class=\"medical medical_review\">Postpartum endometritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=preterm-prelabor-rupture-of-membranes\" class=\"medical medical_review\">Preterm prelabor rupture of membranes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-pelvic-thrombophlebitis\" class=\"medical medical_review\">Septic pelvic thrombophlebitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-group-b-streptococcal-infection-in-pregnant-women-and-neonates\" class=\"medical medical_society_guidelines\">Society guideline links: Group B streptococcal infection in pregnant women and neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=techniques-for-ripening-the-unfavorable-cervix-prior-to-induction\" class=\"medical medical_review\">Techniques for ripening the unfavorable cervix prior to induction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-placental-pathology-report\" class=\"medical medical_review\">The placental pathology report</a></li></ul></div></div>","javascript":null}